Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma.

In our small cohort of heavily pretreated patients with ACC, the combination of LEN/PEM was associated with objective responses in a subset of patients without significant toxicity. This combination should be formally investigated in phase II clinical trial with robust correlative studies to identify predictors for response.